Recipient Selection
Recipient Selection - Related Videos
12:52
Conjugation: A Method to Transfer Ampicillin Resistance from Donor to Recipient E. coli
0 Views •
2023
Source: Alexander S. Gold1, Tonya M. Colpitts1 1 Department of Microbiology, Boston University School of Medicine, National Emerging Infections Diseases Laboratories, Boston, MA First discovered by Lederberg and Tatum in 1946, conjugation is a form of horizontal gene transfer between bacteria that relies on direct physical contact between two bacterial cells (1). Unlike other forms of gene transfer, such as transformation or transduction, conjugation is a naturally occurring process in which...
11:21
Phage Transduction: A Method to Transfer Ampicillin Resistance from Donor to Recipient E. coli
0 Views •
2023
Source: Alexander S. Gold1, Tonya M. Colpitts1 1 Department of Microbiology, Boston University School of Medicine, National Emerging Infections Diseases Laboratories, Boston, MA Transduction is a form of genetic exchange between bacteria that utilizes bacteriophages, or phages, a class of virus that infects exclusively prokaryotic organisms. This form of DNA transfer, from one bacterium to another by way of a phage, was discovered in 1951 by Norton Zinder and Joshua Ledererg, who termed the...
04:05
Subcutaneous Transplantation Assay: A Method to Transplant Melanoma Cells from a Donor to a Recipient Zebrafish Model
0 Views •
2023
This video describes the method for transplantation of tumor cells from the melanoma-bearing donor zebrafish model to an immunocompromised recipient Casper zebrafish. It helps to visualize tumor engraftment and proliferation in the recipient fish.
03:15
A Peptide Array-Based Detection of Anti-donor HLA Alloantibodies in Organ Recipients
0 Views •
2025
This video demonstrates an assay to detect anti-donor HLA alloantibodies in organ recipients. A peptide array is synthesized to represent potential epitopes for antibody-mediated organ rejection. The array is incubated with the recipient's serum, containing alloantibodies that bind to their target epitopes. Antibody binding is detected using chemiluminescence to identify donor-specific HLA epitopes that incite alloantibody reactivity.
02:30
F Plasmid Transfer and Dual Antibiotic Selection in E. coli
0 Views •
2025
Source: Erdogan, F.,et al., Conjugative Mating Assays for Sequence-specific Analysis of Transfer Proteins Involved in Bacterial Conjugation. J. Vis. Exp. (2017)This video demonstrates the procedure for transferring an F plasmid from donor to recipient E. coli cells using a rescue plasmid and selecting transconjugants through dual antibiotic resistance. The process includes mixing bacterial cultures, incubation without shaking, disrupting mating pairs, and plating on selective media to confirm...
FAQs
Clinical teams do not treat eligibility criteria as isolated checkboxes. Diagnostic findings, disease severity, medical history, and anticipated treatment risk are considered together, because one factor can change the significance of another. Standardized criteria promote consistent decisions, while patient-specific review prevents rigid application from obscuring meaningful differences among candidates.
When a donor is involved, compatibility becomes an additional selection consideration alongside the patient’s clinical status. The team must determine whether the proposed match supports a reasonable balance between expected benefit and potential harm. This requirement makes selection more than an assessment of disease severity alone and can influence prioritization among otherwise eligible candidates.
Contraindications are evaluated as factors that may make an intervention unsuitable or increase its potential harm. Rather than considering them separately from the expected benefit, clinicians incorporate them into the broader risk assessment and eligibility review. Identifying these concerns before treatment helps teams exclude inappropriate candidates, clarify uncertainty, and support a more informed consent discussion.
A multidisciplinary team brings different clinical perspectives to the same candidate review. Members can compare diagnostic findings, medical history, disease severity, eligibility requirements, and anticipated risks before reaching a decision. This shared assessment helps apply standardized criteria consistently while retaining patient-specific judgment, which is especially important for complex interventions and treatments with limited availability.
A typical workflow begins with reviewing the patient’s diagnosis and disease severity, followed by examination of medical history and treatment eligibility. The team then assesses potential risks, checks for contraindications, and, when relevant, evaluates donor-recipient compatibility. Finally, clinicians weigh expected benefit against possible harm, discuss the decision with the patient, and document the selection rationale.
Recipient selection is relevant to transplantation, clinical trials, specialized therapies, procedures, and other medical interventions in which eligibility or risk differs among patients. In transplantation, donor-recipient compatibility may be central. In clinical trials, consistent eligibility criteria help identify appropriate participants and make outcome comparisons more interpretable without eliminating the need for patient-specific assessment.
Selection decisions shape which patients receive an intervention, so they also influence how results should be understood. Applying clear criteria can improve safety and make outcomes more comparable across appropriately selected groups. In transplantation and clinical trials, documenting eligibility and risk assessment helps distinguish effects associated with the intervention from differences in the patients chosen to receive it.